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Antisense oligodesoxynucleotide strategies in renal and cardiovascular
disease. Antisense oligodesoxynucleoties (ODN) provide a novel strategy
to inhibit RNA transcription and thereby the synthesis of the gene
product. Because antisense ODN hybridize with the mRNA strand, they
are highly specific. Their backbone structure has been modified to
phosphorothioates or phosphoamidates so that they can better withstand
degradation after delivery. We have shown that antisense ODN are a
useful research tool to elucidate intracellular processes. The example we
provide involves the inhibition of PKC signaling. Furthermore, we have
shown the potential clinical utility of antisense treatment. We successfully
inhibited the expression of the surface adhesion molecule ICAM-1 with
antisense ODN in a model of reperfusion injury. This model is highly
applicable to the problem of delayed graft function in humans. However,
“getting there” is a major problem and clearly less than half the fun.
Cationic substances such as lipofectin have worked sufficiently well in the
experimental setting. Viral gene transfer offers a possibility; however,
viruses produce an additional series of problems. Liposomes may not
provide sufficient transfer efficiency. Coating liposomes with viral fusion
proteins may offer an ideal way with which to deliver the goods into the
cytoplasm of the target cell.
The use of antisense oligodeoxynucleotides (ODN) for the
blockade of gene expression was introduced in 1978 by Zamecnik
and Stephenson [1]. Due to the specificity of Watson-Crick
base-pair hybridization, antisense ODN have been used exten-
sively in attempts to inhibit expression of distinct genes both in
vitro and in vivo. Figure 1 outlines a schematic view of how
antisense ODN probably function to inhibit RNA uptake to
ribosomes and thus, protein transcription. Although their precise
mechanism of action has not been clarified, antisense ODN offer
considerable promise as novel molecular therapeutic agents
against diseases including AIDS, cancer, and inflammatory disor-
ders. Furthermore, antisense ODN have been used in renal and
cardiovascular medicine to unravel pathophysiological mecha-
nisms, and experimentally as therapeutic agents [2]. We will
discuss several aspects of our experience using antisense ODN in
the understanding of renal and vascular pathophysiology, as well
as in experimental therapeutic protocols. Recent improvements in
the design of RNA molecules with modified properties will be
addressed first. Second, the specificity of how antisense ODN can
be used to dissect molecular mechanisms of disease and how
specificity offers new possibilities of drug treatment is discussed.
Third, we will discuss the endothelium as a potential target tissue
for antisense therapy. Finally, new, non-viral, gene transfer tech-
niques that enhance ODN uptake under experimental conditions
and may be useful in future therapeutic trials are presented.
CHEMICAL MODIFICATION OF
OLIGODESOXYNUCLEOTIDE
The naturally occurring phosphodiester-linked ODN that were
used initially were degraded rapidly by cellular nucleases and
therefore could not be used as in vivo therapeutic agents. Thus,
chemically modified antisense ODN were developed that are
more resistant to endogenous degradation. An example of such
stable analogs are oligonucleotides with a phosphorothioate mod-
ified backbone. These compounds are relatively stable and are the
first generation of antisense compounds used in clinical trials [2].
However, phosphorothioates are not ideal and possess several
properties that make it unsuitable for therapeutic purposes. The
main disadvantages of phosphorothioates are low binding affini-
ties for stranded RNA and double-stranded DNA targets com-
pared to natural phosphodiesters [2], and nucleotide independent
binding to a variety of cellular proteins [3]. Subsequently, DNA
analogs with nonphosphodiester backbones have been developed.
A larger number of derivatives are now available in which the
phosphodiester linkage has been replaced but the deoxyribose
structure retained. These derivatives include compounds ranging
from phosphate backbone (phosphodithioates, chimeric meth-
ylphosphonate-phosphodiesters, peptide nucleic acids) and 5-pro-
pynyl-pyrimidine containing oligomers to sugar modifications
(29-substituted ribonucleosides, a-configuration) [4]. However,
only a few of these structures, such as those having a thioformac-
etal or a carboxamide linkage, appear to be good structural DNA
mimics.
Recently, a new type of a deoxyoligonucleotide analog was
synthesized with a modification of the phosphate backbone, where
the O39-P bonds are replaced by N39-P linkages [5, 6]. These
so-called phosphoramidate analogs show several promising fea-
tures. They have an achiral phosphorus-containing, negatively
charged backbone and therefore exhibit good water solubility. In
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addition, they feature improved resistance to nuclease degrada-
tion. Thus, they form very stable sequence-specific duplexes with
single-stranded DNA, RNA, and with themselves. The phospho-
ramidate analogs are also able to form stable triplexes with
double-stranded DNA and RNA under nearly physiological con-
ditions [7]. Phosphoramidates are also more digestion resistant
and display less protein binding than phosphorothioates [8, 9].
Figure 2 shows a schematic of ODN backbone modifications. A
major problem is the large scale synthesis of these compounds.
We have focused our efforts on the synthesis of phosphoramidate
ODN with a method that employs a phosphoramidite amine-
exchange reaction [10]. This method utilizes the corresponding
monomethoxytrityl-protected 39-amino-29,39-dideoxynucleoside-
59-phosphoramidites as building blocks.
SPECIFICITY
Antisense ODN are directed against distinct molecular entities.
Thus, the effective therapeutic use of antisense ODN offers the
possibility to directly interfere with the molecular mechanisms of
the pathophysiological process [11]. Such an approach allows very
specific hypothesis testing. The specificity of the approach enabled
us to directly target molecules with similar properties and struc-
ture such as kinase isoforms from the same kinase family, small
GTP-binding proteins, or subtypes of receptors. We have used the
unique property of antisense treatment to dissect the function of
the various protein kinase C (PKC) isoforms in endothelial cells.
PKC is a group of calcium and phospholipid-dependent protein
kinases (isoforms) with a broad substrate specificity. PKC iso-
forms are involved in signal transduction responses. The enzyme
family was first described by Nishizuka and colleagues [12]. PKC
is ubiquitously distributed and plays an important role in the
control or regulation of many different biological processes [12].
In endothelial cells, PKC has been implicated in the expression
and regulation of adhesion molecules [13], in the expression of
endothelin-1 [14], and in the proliferative response to hormones
and growth factors [15]. Furthermore, endothelial PKC appears to
mediate the intracellular effects of shear stress [8] and may also be
important to angiogenesis [16]. Investigating PKC is difficult
because PKC is not a single entity, but consists of several distinct
isoforms with different regulatory and biochemical properties
[13]. The PKC isoforms are expressed on separate genes and may
play different roles in cell signaling and cell function [12].
Presently, the mammalian PKC family consists of 12 different
polypeptides: a, bI, bII, g, d, e, z, h, u, t, l and m. An analysis of
isoform expression and distribution is necessary to investigate
Fig. 1. Schematic diagram of antisense
oligodesoxynucleotide (ODN)-mediated effects
on protein expression.
Fig. 2. Backbone modifications of oligodeoxynucleotide (ODN; see text).
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PKC’s role in signaling. Since PKC plays an important role in the
intracellular signal transduction pathways of the endothelium and
is involved in various functions of the endothelium such as
expression of adhesion molecules and regulation of the perme-
ability barrier, defining which PKC isoform mediates a specific
signal is of considerable interest. However, thus far no specific
inhibitors for the different PKC isoforms are available.
This problem would appear ideal for an antisense ODN-based
approach. We observed that hyperglycemia increased endothelial
cell-layer permeability via a PKC-mediated mechanism. To deter-
mine which PKC isoform was responsible, we relied on an
antisense strategy. We concentrated on the PKC isoforms a and e,
because our confocal immunofluorescent data implicated those
isoforms. These data are reviewed in Figure 3. We included
antisense to PKC z as an additional control. An antisense ODN
(ISIS 3521) was selected against the human 39-untranslated region
derived from the human PKC a sequence (European Molecular
Biology Laboratories data base, Heidelberg, Germany). The
antisense sequence used for PKC a was (59 GTT.CTC.GCT.G-
GT.GAG.TTT CA 39). The sense ODN sequence (59
TG.AAA.CTC.ACC.AGC.GAG.AAC 39), a reverse ODN se-
quence (59 AC.TTT.GAG.TGG.TCG.CTC.TTG 39) and a scram-
bled version (59 GAG.TTG.CTT.GCT.TAT.CGG.TC 39) were
used as controls. The antisense sequence used for PKC e against
the human AUG start codon was (59 GCC.ATT.GAA.CAC.TAC-
CAT 39).
Figure 4 shows a Western blot analysis of PKC a, PKC e, and
PKC z after transfection with antisense ODN. Antisense ODN led
to a down-regulation of the respective PKC isoforms to 40 to 30%
as compared to control. In contrast, protein levels of PKC e were
not affected by exposure of the endothelial cells to antisense ODN
against PKC a.
These antisense ODN were used to influence the glucose-
induced increase in endothelial cell permeability, as shown in
Figure 5. Antisense ODN for PKC a almost completely inhibited
the increase in glucose-induced endothelial cell permeability.
Sense and scrambled ODN for PKC a had no effect on the
glucose-induced permeability. In contrast to the effects of anti-
sense against PKC a, the antisense ODN against PKC e did not
reduce the glucose-induced permeability significantly. This expe-
rience demonstrates that an antisense ODN approach can be used
for delineation of the specific PKC effects in signal transduction
and cell physiology. Early experiments have shown that this
approach can also be used in vivo. Intraperitoneal injection of
ODN in mice caused a dose-dependent, ODN sequence-depen-
dent reduction in PKC a mRNA [17]. Thus, this approach may
possibly be applied to prevent glucose-induced vascular changes in
vivo. We are presently using this approach for the treatment of
diabetes-induced changes in the rat.
The utility of antisense to block intracellular signaling processes
is of course not limited to PKC. Other examples include antisense
directed at inhibiting the production of GTP-binding proteins,
other kinases and transcription factors. Several groups have
shown that antisense against cdc2 kinases exert specific effects in
vascular tissue [18, 19]. Nikajima et al have used antisense ODN
for the inhibition of NFkB [20]. In addition, antisense can also be
used to investigate subtypes of membrane-bound receptors, such
as the FGF receptor family [21, 22] or the rapidly expanding
family of VEGF receptors [23]. Still other examples include
targeting of proteases or components of the cell cycle [24–26].
Fig. 3. Effect of high glucose (20 mM) on the intracellular distribution of protein kinase C (PKC) isoform a, e, and z under control conditions (left
panel, control), and after 5, 10 and 30 minutes. High glucose induced changes in intracellular distribution of PKC isoform a and e. In contrast, PKC
z was not influenced by high glucose. The graded color bar indicates different PKC concentrations whereby blue, green, yellow and red represent
increasing PKC concentrations, respectively. The publication of this figure in color was made possible by a grant from Perkin Elmer, Applied Biosystems
Division, Foster City, California, USA.
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TARGETING
Identifying potential targets for antisense strategies is easy;
however, getting the antisense to the targets can be insurmount-
ably difficult. Fortunately, since antisense ODN are small mole-
cules they cross the cell membrane more easily than other genetic
material. When injected into the venous circulation, antisense
ODN demonstrate a rather high first pass effect and are rapidly
taken up by the liver. However, about 1 to 3% of the antisense
ODN reaches the coronary circulation, and between 0.5 and 1%
arrives in the kidney after intravenous injection. Our own exper-
iments show that the addition of cationic lipids considerably
increase the percentage of renal uptake. The uptake into the renal
vasculature takes place within minutes. Most of the circulating
ODN are taken up by the endothelium. In our experience, even
the intimal layers of vascular cells are not reached by circulating
antisense ODN. However, other groups have observed an anti-
sense effect in media vascular smooth muscle cells [27]. Conceiv-
ably, injured vascular tissue or damaged enothelial cells may
exhibit altered uptake characteristics. In addition, cells adjacent to
the endothelium and not shielded by the basal lamina, such as
mesangial cells in the kidney, may also take up circulating ODN
[28]. The rapid uptake by the endothelium makes this tissue a
suitable target for antisense. The endothelium may be an inter-
esting target for gene therapy, because endothelial cells play a
major role in the development of all chronic vascular and renal
diseases.
Adhesion of leukocytes to the endothelium plays an important
role in such diverse processes as inflammation, transplantation,
and atherosclerosis. Reperfusion injury involves activated leuko-
cytes with enhanced adhesiveness to endothelium [29]. Adhesion
Fig. 4. Western blot analysis of antisense
oligodesoxynucleotide (ODN) against protein
kinase C (PKC) a, e and z in endothelial cells.
Western blots were stained with PKC specific
antibodies as indicated. Antisense ODN against
PKC a led to a significant downregulation of
PKC a, while PKC e and z protein levels were
not influenced. Antisense ODN against PKC e
and PKC z, respectively, also led to a specific
inhibition of PKC isoform expression without
influencing the protein levels of the other PKC
isoforms.
Fig. 5. Effect of antisense
oligodesoxynucleotide (ODN) against protein
kinase C (PKC) a, sense, scrambled ODN, or
antisense against PKC e and z on glucose (20
mM)-induced endothelial cell permeability.
Endothelial cells were exposed to ODN with
lipofectin (10 mg/ml) 24 hours before exposure
to 20 mM glucose. Antisense against PKC a
significantly reduced the glucose-induced
permeability (P , 0.01), while the control sense
and scrambled ODN, the ODN against PKC e
and PKC z, or lipofectin alone, had no
significant effect.
Haller et al: Antisense oligodesoxynucleotides 1553
molecule mediated, neutrophil endothelial binding is inherent to
this process [30]. The leukocyte b2 integrin complex (CD11/
CD18) interacts with the endothelial ligand intercellular adhesion
molecule-1 (ICAM-1). The initial rolling of neutrophils is medi-
ated by the selectins, while CD11/CD18-ICAM-1 interactions are
responsible for leukocyte adhesion and diapedesis [31]. Studies in
liver, brain, and myocardium showed that ICAM-1 is up-regulated
during ischemia-reperfusion [30]. Antibodies against either CD11/
CD18 or ICAM-1 prevented tissue damage and protect organ
function in other studies [32–34]. We used antisense ODN for
ICAM-1 to influence the expression of adhesion molecules and to
prevent reperfusion injury in the ischemic kidney of the rat.
Phosphorothioate oligodeoxyribonucleotides (ODN) were used
and an antisense ODN (ISIS 1939) against the human 39 untrans-
lated region derived from the rat ICAM sequence RSICAM and
the human ICAM-1 sequence HSICAM01 (European Molecular
Biology Laboratories data base) selected [35, 36]. For the rat
experiments, we compared rat and human sequence data and used
the rat homologue to ISIS 1939 (59 ACC GGA TAT CAC ACC
TTC CT 39). The reverse ODN sequence was used as control. As
in the previous experiments, a cationic lipid was used solution to
enhance ODN uptake.
From preliminary in vitro experiments, a lipofectin concentra-
tion of 0.8 mg/mg DNA and a ODN concentration of 2 mg/kg
body wt was chosen for the in vitro studies. Figure 6 shows the
effect of reverse and antisense oligonucleotides on expression of
ICAM-1 in renal cortical vessels 24 hours after 30 minutes of
ischemia. The saline injected control showed ICAM-1 staining
along the vascular intima. This staining was decreased in antisense
ODN treated animals. The reverse ODN treated animals, on the
Fig. 6. Effect of sense and antisense oligonucleotides on ICAM-1
expression in rat kidney. Upper panel shows immunohistochemical
staining for ICAM-1 in ischemic animals with saline treatment (left),
antisense oligonucleotides (ODN) treatment (middle) and sense ODN
treatment (right) (representative of 30 photomicrographs). Lower panel
shows the densitometric data from these sections (N 5 30, *P , 0.05).
Ischemia induced a marked increase in ICAM-1 expression along the
endothelial cell lining of the blood vessels and in the peritubular area.
Antisense ODN prevented the ischemia-induced increase in ICAM-1
expression, both in the vasculature and in the peritubular area; reverse
ODN had no effect. The publication of this figure in color was made
possible by a grant from Perkin Elmer, Applied Biosystems Division,
Foster City, California, USA.
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other hand, showed prominent ICAM-1 staining. In antisense
treated animals, renal function was preserved and perivascular
leukocyte infiltration was inhibited.
We believe that the antisense approach to acute renal failure
and reperfusion injury could have great clinical utility. We do not
envision prophylactic preoperative antisense ODN treatment in
patients. Instead, we believe such an approach would be both
more valuable and practical in transplantation medicine. For
instance, cadaveric donor kidney are routinely stored in Collins or
similar solutions for 12 to 72 hours before transplantation.
Delayed graft function from ischemia and reperfusion injury is a
major post-transplant problem and has a direct negative impact
on long-term graft survival [36]. Transplanted hearts and livers
also are subject to reperfusion injury and ICAM-1 seems to play
a role in acute and chronic rejection [37–40]. The antisense ODN
treatment is not subject to the same immunological problems that
accompany the use of antibodies directed against adhesion mol-
ecules. We envision a multiple antisense ODN treatment of
transplant grafts directed against a variety of adhesion molecules
associated with reperfusion injury.
TRANSFER
Our experiments demonstrate that antisense ODN can be
successfully used for the treatment of endothelial cells disorders.
However, a limiting step in these investigations is still the low
uptake of ODN in the endothelium. Relatively high concentra-
tions of ODN have to be injected in order to achieve a significant
down-regulation of the targeted protein. More effective gene
transfer techniques may reduce the costs of antisense ODN
therapeutic approaches, and may help to target cells within the
vascular wall or other organs. For gene transfer two main
approaches, viral gene transfer and non-viral techniques, have
been used. Viral gene transfer techniques show high efficiency,
but potentially cause viral infection, activation of oncogenes and
autoimmune response. Newman et al showed that adenovirus-
mediated gene transfer into rabbit arteries results in prolonged
Fig. 7. Schematic diagram of transfection
using liposomes containing F-protein, HN-
protein and DNA. (1) Neutral liposomes
containing F-protein and HN-protein from
Sendai virus as well as therapeutical DNA are
loaded for gene therapy approaches. (2) The
HN binds to its receptor sialic acid. (3) The
liposome content is released into the nucleus.
(4) The therapeutic DNA enters into the
nucleus and transcription begins.
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vascular cell activation, inflammation and neointimal hyperplasia
[41]. Liposome vectors contain no viral sequences and possess the
desired safety profile [42, 43]. However, the liposomal approach
routinely results in efficiencies below 1% [43, 44]. Several tech-
niques have been put forward to enhance gene uptake by lipo-
somes. Improvement of the liposomal method was demonstrated
by Kaneda et al [45], who prepared DNA-loaded liposomes
together with gangliosides and inactivated Sendai virus particles.
Several reports have recently demonstrated that Sendai virus-
coated liposomes can mediate transfer of DNA, antisense ODN,
and double stranded DNA as a decoy. An HVJ-liposome can
encapsulate DNA up to 100 kbp [46]. Using HVJ-liposomes
associated with gangliosides and the nuclear protein HMG-1
(non-histone chromosomal protein, high mobility group 1),
Kaneda et al successfully introduced the entire human insulin
gene into adult rat liver. The transcript amount of the insulin gene
co-introduced with HMG-1 was more than 10 times greater that
of the gene co-introduced with bovine serum albumin alone. In
vivo insulin gene expression was also possible [46]. Tomita et al
used the same approach in introducing a reporter gene into rat
kidney. In 1993, Isaka et al demonstrated that transforming
growth factor-beta (TGF-B) or platelet-derived growth factor-
beta (PDGFB) cDNA can be transported into rat kidney with
HVJ-liposomes to induce glomerulosclerosis.
The HVJ-liposome method of gene transfer has also been used
successfully in the cardiovascular system. For instance, the cDNAs
of the angiotensin converting enzyme (ACE) and renin genes
were transfected into cultured vascular smooth muscle cells in
vitro as well as into rat carotid artery in organ culture [47].
Morishita et al measured increased ACE activity after transfec-
tion of ACE into intact rat carotic arteries. They also demon-
strated that high levels of atrial natriuretic peptide (ANP) was
secreted by cultured endothelial cells [47]. HVJ-liposomes loaded
with eNOScDNA restored eNOS expression in the vessel wall and
inhibited neointimal vascular lesion after balloon injury [48].
The HVJ-liposome mediated transfer is also applicable for
antisense ODN delivery. For instance, this delivery system was
also used for antisense ODN directed at cdk 2 kinase oligonucle-
otides. The cyclin-dependent kinase is activated in the rat carotid
artery after balloon angioplasty injury and is probably responsible
for smooth musle proliferation. Morishita et al showed that
intimal hyperplasia after vascular injury is inhibited by specific
antisense oligonucleotides [49]. Furthermore, a gene therapy
strategy using a transcription factor decoy of the E2F binding site
inhibits smooth muscle proliferation in vivo [50].
A major disadvantage of this promising gene transfer approach
is the tedious and time consuming preparation of the viral
particles. Thus far, no preparation that would pass GMP criteria
for human use has been demonstrated. We have therefore started
to develop a gene delivery system containing neutral liposomes
and recombinant viral surface fusion proteins. Yeagle reported
that a fusion peptide, isolated from the remainder of F1, desta-
bilizes membranes [51]. Therefore, he hypothesized that contact
between the a hydrophobic sequence of the fusion peptide of F
and the target membrane is capable of substituting for bilayer-
bilayer contact. The fusion process differs from the receptor-
mediated endocytosis with fusion of endosomes and lysosomes at
acidic pH used by influenza virus [52]. A schematic diagram of
transfection with liposomes outfitted with viral fusion proteins is
shown in Figure 7.
Expression of recombinant viral fusion proteins is not an easy
task. Pomaskin, Veit and Schmidt used a baculovirus system and
found incomplete processing and membrane transport of F-
protein, due to the different glycosylation and protein transport
pathways in invertebrate cells [53]. Construction of recombinant
vaccinia virus expressing Sendai-F-protein resulted in a biologi-
cally inactive protein [53], probably because the severe cytopathic
effects of vaccinia virus disturbs the expression of the activity.
Using PCR-mutagenesis we added a factor Xa cleavage site into
the F-cDNA to obtain the correctly processed and active F-
protein. For future purification of the protein we fused a histidine
sequence coding at the end of the F- and HN-cDNA. The vector
pcDNA3 carries the correspondent cDNAs under the control of
the cytomegalovirus promoter. Furthermore, we cloned our con-
structs into the vector pzeoSV2. Genes cloned into pZeoSV2 are
expressed from the Simian virus 40 early promoter for high level
transient and stable expression in mammalian cells. Then, as
shown in Figure 7, it should be possible to use the purified
proteins to generate fusion protein coupled liposomes. Our
method differs from commonly used HVJ-liposomes because we
do not use the whole inactivated Sendai virus. Instead, we
integrate the two recombinant proteins from Sendai virus into the
liposomes. In vivo experiments will show whether these constructs
will diminish cell toxicity, immune response and inflammation.
PERSPECTIVES
Antisense strategies have been termed the “poor man’s road to
gene therapy.” The ODN have been made more robust by means
of a phosphoramidate backbone. The tremendous specificity of
antisense ODN was demonstrated in the PKC experiments con-
ducted by our group, as well as in a host of studies by other
investigators. Since the inhibition of mRNA transcription by
antisense ODN is transient, the therapeutic potential may be
limited. However, our approach to use antisense to inhibit the
development of reperfusion injury and thereby delayed graft
function in transplanted kidneys may be an ideal clinical setting to
use antisense ODN. As in all “gene therapy” strategies, delivery is
a serious problem. We believe that eventually, liposomes coated
with viral fusion proteins will offer an acceptable, highly efficient
delivery system. In that way, the poor may indeed inherit at least
a part of the earth.
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